ArticleFrontiers in oncology2025

Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors.

Jinming Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.